In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Private label miconazole combo packs

This article was originally published in The Tan Sheet

Executive Summary

Alpharma receives approval April 16 for ANDA 74-926 and Perrigo, April 20 for ANDA 75-926, allowing both to market three-day miconazole vaginal antifungal treatment combination packs. Equivalent to the reference drug J&J's Monistat 3 Combination Pack, each contains three 200 mg miconazole nitrate suppositories and a 9 g tube of 2% miconazole nitrate cream. Waxman/Hatch marketing exclusivity for Monistat 3 ended April 16, opening up competition for the brand's 5.6% dollar share, reported by Chicago-based Information Resources, Inc. to be worth nearly $68 mil. at U.S. food, drug and mass merchandisers for the 52 weeks ended March 28

You may also be interested in...



J&J Monistat 3 Combination Pack Cream Extension Clears FDA

Johnson & Johnson Personal Products will begin shipping a Monistat 3 Combination Pack cream line extension to food, drug and mass outlets in the second quarter, the firm said Feb. 9.

J&J Monistat 3 Combination Pack Cream Extension Clears FDA

Johnson & Johnson Personal Products will begin shipping a Monistat 3 Combination Pack cream line extension to food, drug and mass outlets in the second quarter, the firm said Feb. 9.

J&J Monistat 3 Combination Pack Cream Extension Clears FDA

Johnson & Johnson Personal Products will begin shipping a Monistat 3 Combination Pack cream line extension to food, drug and mass outlets in the second quarter, the firm said Feb. 9.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS089714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel